# 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma

> **NCT03051555** · NA · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 60 (estimated)

## Conditions studied

- Lymphoma, Extranodal NK-T-Cell

## Interventions

- **DEVICE:** 18F-FDG PET/ CT

## Key facts

- **NCT ID:** NCT03051555
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03051555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03051555, "18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03051555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*